All Takeda wants for its billion-dollar gene therapy spending spree is functional cures

All Takeda is trying to do with its billions-of-dollars worth of licensing deals in gene therapy is cure rare disease. Simple, right?

Madhu Natarajan, head of Takeda’s Rare Disease Drug Discovery unit, knows that to many, cure is a “four-letter word.”